Although only 5–10% of ovarian cancers are directly attributable to a germline mutation in BRCA1 or 2, there is a growing body of evidence to suggest that additional mechanisms of BRCA dysfunction are involved in the pathogenesis of ovarian cancer (26, 38, 39). This evidence concerns the gene BRCA1 and ovarian carcinoma.